What is MDS therapy?

Therapy-related myelodysplastic syndromes (t-MDS) are defined as MDS occurring as a complication of cytotoxic chemotherapy and/or radiation administered for an antecedent neoplastic or non-neoplastic disorder.

What Can MDS transform to?

MDS can transform into acute leukemia, which is often accompanied by a poor prognosis.

What is cytogenetic response in MDS?

A complete cytogenetic response is defined as a resolution of all chromosomal abnormalities. A partial cytogenetic response is defined as 50% or more reduction in chromosomal abnormalities.

Who MDS defining cytogenetic abnormalities?

Different cytogenetic abnormalities are considered MDS-defining [20]. The presence monosomy 5, 7, or 13; 5q, 7q and 13q deletions; i(17p) and t(17p); 11q deletion; 9q or 12p deletion or t(12p), idic (X)(q13) allows for the diagnosis of MDS even in the absence of dysplastic changes.

Can you have MDS with no blasts?

In MDS, the blasts do not mature properly, so there may be too many blasts and not enough mature cells. For a diagnosis of MDS, a patient must have less than 20% blasts in the bone marrow and blood.

Which is the most common cytogenetic abnormality in adult myelodysplastic syndrome MDS?

Deletions of the long arm of chromosome 5 (5q) are the most frequently found chromosomal abnormalities in MDS (up to 15% of diagnosed cases) 3,8 .

What are cytogenetic studies?

The study of chromosomes, which are long strands of DNA and protein that contain most of the genetic information in a cell. Cytogenetics involves testing samples of tissue, blood, or bone marrow in a laboratory to look for changes in chromosomes, including broken, missing, rearranged, or extra chromosomes.

What is a cytogenetic abnormality?

Definition. An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material. [ from NCI]

What is blast percentage in MDS?

MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood. MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood.

Does cytogenetic status affect MDS diagnosis in patients with MDS?

Cytogenetic analysis was completed in 214 MDS patients. There was no significant difference in patient characteristics, age, sex, and clinical diagnosis between these and patients for whom cytogenetic status was not known.

How common are cytogenetic abnormalities in de novo myelodysplastic syndrome (MDS)?

Cytogenetic abnormalities are identified at diagnosis in 30% to 70% patients with de novo myelodysplastic syndrome (MDS); the frequency increasing with higher risk disease. 1, 2 Chromosome translocations in MDS are rare and the most common karyotypic lesions involve chromosomes 8 (gain), 5 (loss/deletion), and 7 (loss/deletion).

Is exposure history associated with cytogenetic abnormalities in patients with myelodysplastic syndromes?

Patients with myelodysplastic syndromes (MDS) have high frequencies of cytogenetic abnormalities and evidence is accumulating of associations between exposure history and primary MDS. The objective of this article is to examine the relationship between histories of occupational or environmental exposure and presence of cytogenetic abnormalities.

Is there an association between occupational exposure and cytogenetic abnormality in MDS?

Several previous reports of association between occupational exposure and cytogenetic abnormality in MDS have involved small numbers of patients 26, 27 and have been based on internal comparisons between cytogenetically normal and abnormal patients.